Last reviewed · How we verify
Esmolol Injection [Brevibloc]
Esmolol is a selective beta-1 adrenergic receptor antagonist that rapidly blocks sympathetic stimulation of the heart, reducing heart rate and blood pressure.
Esmolol is a selective beta-1 adrenergic receptor antagonist that rapidly blocks sympathetic stimulation of the heart, reducing heart rate and blood pressure. Used for Intraoperative and postoperative tachycardia, Intraoperative and postoperative hypertension, Supraventricular tachycardia.
At a glance
| Generic name | Esmolol Injection [Brevibloc] |
|---|---|
| Also known as | Anatomical Therapeutic Chemical (ATC) code: C07AB09, Esmolol Hydrochloride |
| Sponsor | Consorcio Centro de Investigación Biomédica en Red (CIBER) |
| Drug class | Beta-1 selective adrenergic antagonist |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Esmolol competitively inhibits beta-1 adrenergic receptors on cardiac tissue, decreasing the effects of catecholamines and reducing cardiac contractility and heart rate. It has a very short half-life (approximately 9 minutes) due to rapid metabolism by red blood cell esterases, making it suitable for acute intravenous use in perioperative settings. Its cardioselective beta-1 blockade provides hemodynamic control with minimal effects on beta-2 receptors in the lungs.
Approved indications
- Intraoperative and postoperative tachycardia
- Intraoperative and postoperative hypertension
- Supraventricular tachycardia
Common side effects
- Hypotension
- Dizziness
- Somnolence
- Nausea
- Headache
- Infusion site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: